Fig. 2: Characterisation of MCF7–WT, and isogenic MCF7–C1, and MCF7–BRCA1+/− cell lines.
From: Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
a Sequence of heterozygous pathogenic BRCA1 c.2432_2433del variant introduced by CRISPR-Cas9. b Relative proliferation of MCF7–WT and clonally expanded CRISPR-Cas9 MCF7–C1 and MCF7–BRCA1+/− cells for 72 h post seeding. Relative expression of c BRCA1, d ESR1, e CYP1A1, and f SULT1A1 for MCF7–WT, MCF7–C1 and MCF7–BRCA1+/− cells. 4-OHE2 4-hydroxyestradiol, MMC Mitomycin C, Error bars = standard error of the mean; ns = p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; n = 3 independent biological replicates; unpaired two-sided t-test.
